Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.

The US president vows "major" tariffs on imported medicines - raising fears of an increase in costs for Americans.

Consumers won’t be buying as many gadgets during the potential downturn that’s slamming tech stocks, forecasts Daniel Newman ...

The $1.7 trillion revenue prescription drug industry has a relatively robust immunity to tariffs. Last Wednesday, when U.S.

Stocks of several large-cap pharmaceutical companies plummeted on Friday after China hit back with retaliatory tariffs of 34% on all U.S. imports, escalating fears of a global recession. This move ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter's winners and losers.

What impact will this have? David Anchell is the founder and managing director of specialist pharma and industrial company Camida and joined us on Newstalk Breakfast this monring.

Could K-Beauty Benefit from Big Pharma’s Challenges? As Western pharmaceutical giants navigate potential supply chain disruptions and pricing challenges, K-beauty’s accessibility and ...